- Home
- GLUE vs SOR Comparison
GLUE vs SOR Comparison
Compare GLUE & SOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLUE
- SOR
- Stock Information
- Founded
- GLUE 2019
- SOR 1968
- Country
- GLUE United States
- SOR United States
- Employees
- GLUE N/A
- SOR N/A
- Industry
- GLUE Biotechnology: Pharmaceutical Preparations
- SOR Investment Managers
- Sector
- GLUE Health Care
- SOR Finance
- Exchange
- GLUE Nasdaq
- SOR Nasdaq
- Market Cap
- GLUE 351.2M
- SOR 364.9M
- IPO Year
- GLUE 2021
- SOR N/A
- Fundamental
- Price
- GLUE $4.80
- SOR $44.50
- Analyst Decision
- GLUE Buy
- SOR
- Analyst Count
- GLUE 2
- SOR 0
- Target Price
- GLUE $13.50
- SOR N/A
- AVG Volume (30 Days)
- GLUE 369.2K
- SOR 16.2K
- Earning Date
- GLUE 08-07-2025
- SOR 01-01-0001
- Dividend Yield
- GLUE N/A
- SOR 7.24%
- EPS Growth
- GLUE N/A
- SOR N/A
- EPS
- GLUE 0.29
- SOR 6.50
- Revenue
- GLUE $177,986,000.00
- SOR N/A
- Revenue This Year
- GLUE $83.76
- SOR N/A
- Revenue Next Year
- GLUE N/A
- SOR N/A
- P/E Ratio
- GLUE $16.32
- SOR $6.41
- Revenue Growth
- GLUE 2990.57
- SOR N/A
- 52 Week Low
- GLUE $3.50
- SOR $36.41
- 52 Week High
- GLUE $12.40
- SOR $42.75
- Technical
- Relative Strength Index (RSI)
- GLUE 51.69
- SOR 63.93
- Support Level
- GLUE $4.54
- SOR $43.65
- Resistance Level
- GLUE $4.93
- SOR $44.86
- Average True Range (ATR)
- GLUE 0.21
- SOR 0.63
- MACD
- GLUE 0.06
- SOR 0.05
- Stochastic Oscillator
- GLUE 81.43
- SOR 68.46
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.